Compare Stocks

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NEO NeoGenomics	$13.77 +0.7%	$15.15	$11.03 ▼ $21.22	$1.76B	1.1	904,194 shs	913,517 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NEO NeoGenomics	-1.23%	-5.39%	-5.98%	-11.91%	-11.00%

Bitcoin Rockets To Record High But Buy THIS Instead (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NEO NeoGenomics	1.4385 of 5 stars	3.4	2.0	0.0	0.0	0.6	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NEO NeoGenomics	2.80	Moderate Buy	$19.50	41.61% Upside

Current Analyst Ratings

Latest ELM, NEO, and SCPA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
2/26/2024	NEO NeoGenomics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$18.00 ➝ $20.00
2/22/2024	NEO NeoGenomics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $19.00
2/21/2024	NEO NeoGenomics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/21/2024	NEO NeoGenomics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $24.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NEO NeoGenomics	$591.64M	2.97	$0.28 per share	49.06	$7.39 per share	1.86

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NEO NeoGenomics	-$87.97M	-$0.70	N/A	N/A	N/A	-14.87%	-4.13%	-2.33%	4/30/2024 (Confirmed)

Latest ELM, NEO, and SCPA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/30/2024	N/A	NEO NeoGenomics	-$0.0270	N/A	+$0.0270	N/A	N/A	N/A
2/20/2024	Q4 2023	NEO NeoGenomics	-$0.07	-$0.02	+$0.05	$0.07	$152.90 million	$155.55 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NEO NeoGenomics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NEO NeoGenomics	0.57	6.20	5.95

Ownership

Institutional Ownership

Company	Institutional Ownership
NEO NeoGenomics	98.50%

Insider Ownership

Company	Insider Ownership
NEO NeoGenomics	1.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
NEO NeoGenomics	2,100	127.67 million	126.01 million	Optionable

ELM, NEO, and SCPA Headlines

Source	Headline
	NeoGenomics Announces Senior Leadership Promotions businesswire.com - April 18 at 7:05 AM
	NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024 businesswire.com - April 9 at 7:00 AM
	NSCLC Patients Who Should Get First-Line EGFR Inhibitors Are on Immunotherapy Instead, Study Finds precisionmedicineonline.com - April 3 at 8:11 PM
	Redwood Investments LLC Takes $2.40 Million Position in NeoGenomics, Inc. (NASDAQ:NEO) marketbeat.com - April 1 at 6:48 AM
	Federal Circuit Dubious About Harm of Cancer Test’s Sales Ban news.bloomberglaw.com - March 31 at 11:55 PM
	SG Americas Securities LLC Trims Position in NeoGenomics, Inc. (NASDAQ:NEO) marketbeat.com - March 30 at 4:17 AM
	An egg-ceptional Charity Easter Egg collection cambridgenetwork.co.uk - March 28 at 2:26 PM
	NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting businesswire.com - March 27 at 8:30 AM
	American Cancer Society Relay for Life Saturday at NeoGenomics in Fort Myers lehighacrescitizen.com - March 22 at 9:15 PM
	Commit To Purchase NeoGenomics At $10, Earn 9.1% Annualized Using Options nasdaq.com - March 21 at 7:25 PM
	Neogenomics Pokes Up On Unveiling ESG Report msn.com - March 20 at 4:48 PM
	NeoGenomics (NASDAQ:NEO) Trading Up 5.3% marketbeat.com - March 20 at 4:31 PM
	All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy zacks.com - March 20 at 1:01 PM
	Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect? zacks.com - March 20 at 10:56 AM
	NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report businesswire.com - March 20 at 7:00 AM
	Public Sector Pension Investment Board Sells 68,768 Shares of NeoGenomics, Inc. (NASDAQ:NEO) marketbeat.com - March 20 at 4:18 AM
	NeoGenomics Inc. barrons.com - March 14 at 12:46 PM
	Omics Lab Services Market Report 2024 - Innovations in Genomics and Big Data Analytics au.finance.yahoo.com - March 11 at 9:27 PM
	NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference businesswire.com - March 1 at 7:05 AM
	Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know finance.yahoo.com - February 28 at 1:55 PM
	Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know zacks.com - February 28 at 10:56 AM
	NeoGenomics (NEO) Price Target Increased by 6.33% to 21.79 msn.com - February 23 at 2:17 PM
	NEO Mar 2024 10.000 put finance.yahoo.com - February 23 at 8:49 AM
	NeoGenomics stock surged but technicals point to a pullback kalkinemedia.com - February 22 at 10:36 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

NeoGenomics

NASDAQ:NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial